Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in Medullary Thyroid Carcinoma
NCT02586350Phase 3Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2015
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in medullary thyroid carcinoma (MTC) comparing Anlotinib Arm with Placebo Arm (2 arms). Primary endpoint: Progression-Free Survival at 24 months. Started Jul 2015; status: completed.
02
Drugs
anlotinib
03
Conditions
medullary thyroid carcinoma (MTC)
Beyond the preview
Go deeper on NCT02586350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02586350.